tradingkey.logo

Zentalis Pharmaceuticals Inc <ZNTL.OQ> expected to post a loss of 71 cents a share - Earnings Preview

ReutersFeb 24, 2025 11:22 AM
  • Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show no change in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00​, above​ its last closing price of $2.32. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.88

-0.91

-0.56

Beat

38.5

Jun. 30 2024

-0.87

-0.84

-1.24

Missed

-47.5

Mar. 31 2024

-0.76

-0.77

0.14

Beat

118.3​

Dec. 31 2023

-0.94

-0.92

-0.93

Missed

-1.5

​​Sep. 30 2023

-0.91

-0.91

-0.79

Beat

13.3

Jun. 30 2023

-1.02

-1.04

-1.85

Missed

-78.3​

Mar. 31 2023

-0.98

-1.02

-1.07

Missed

-5

Dec. 31 2022

-1.01

-1.06

-0.92

Beat

13.2

This summary was machine generated February 24 at 11:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI